sub:assertion {
d:DB08831 v:identifier "DB08831" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB08831" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB08831> ;
dv:drugbank-id "DB08831" ;
dv:x-cas <
http://bio2rdf.org/cas:154-17-6> ;
dv:x-chebi <
http://bio2rdf.org/chebi:15866> ;
dv:x-kegg <
http://bio2rdf.org/kegg:C00586> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:2-Deoxy-D-glucose> ;
dct:description "2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). By using positron emission tomography (PET), radiolabelled 2-deoxyglucose can determine glucose metabolism, which is altered in diseases such as cardiovascular disease, tumors, and Alzheimer's disease. Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent. Concerning the former, 2- deoxyglucose was used as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors (lung, breast, pancreas, head, neck, and gastric tumors). The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately, cell survival. With respect to antiviral therapy, 2-deoxyglucose was shown to be effective against herpes simplex virus by affecting the virus' ability to penetrate cells. As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. In this condition, 2-deoxyglucose represses the expression of certain proteins that are at high levels after a seizure. Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent."@en ;
dct:identifier "drugbank:DB08831" ;
dct:title "2-deoxyglucose"@en ;
a dv:Drug ;
rdfs:label "2-deoxyglucose [drugbank:DB08831]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB08831> .
}